Posters

EMBL: Developing a New Generation of First-in-class High Diversity Microbiome Biotherapeutics to Treat Life-threatening Diseases

Date : septembre 18, 2018

MaaT Pharma and Lutech Sign Licensing Agreement for Graft-vs-Host Disease

MaaT Pharma Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic